Analysts Expect RadNet, Inc. (NASDAQ:RDNT) to Post -$0.02 Earnings Per Share

Equities research analysts expect RadNet, Inc. (NASDAQ:RDNTGet Rating) to report ($0.02) earnings per share (EPS) for the current quarter, Zacks reports. Two analysts have made estimates for RadNet’s earnings, with the highest EPS estimate coming in at ($0.01) and the lowest estimate coming in at ($0.02). RadNet reported earnings per share of $0.04 during the same quarter last year, which would indicate a negative year-over-year growth rate of 150%. The firm is scheduled to issue its next earnings report on Monday, January 1st.

According to Zacks, analysts expect that RadNet will report full-year earnings of $0.37 per share for the current fiscal year, with EPS estimates ranging from $0.36 to $0.37. For the next financial year, analysts forecast that the business will report earnings of $0.62 per share, with EPS estimates ranging from $0.58 to $0.66. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of research firms that that provide coverage for RadNet.

RadNet (NASDAQ:RDNTGet Rating) last announced its quarterly earnings data on Tuesday, March 1st. The medical research company reported $0.13 earnings per share for the quarter, missing the consensus estimate of $0.19 by ($0.06). RadNet had a return on equity of 10.91% and a net margin of 1.88%. The business had revenue of $333.15 million for the quarter, compared to the consensus estimate of $347.96 million.

Several brokerages recently weighed in on RDNT. TheStreet downgraded RadNet from a “b-” rating to a “c” rating in a research report on Tuesday, March 15th. StockNews.com began coverage on RadNet in a research report on Thursday, March 31st. They set a “hold” rating for the company. Finally, Zacks Investment Research downgraded RadNet from a “hold” rating to a “sell” rating in a research report on Friday, March 4th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company’s stock. According to data from MarketBeat.com, RadNet currently has an average rating of “Hold” and a consensus target price of $38.00.

Shares of RDNT stock traded down $0.78 on Friday, hitting $20.08. 229,056 shares of the company’s stock were exchanged, compared to its average volume of 183,885. The company has a debt-to-equity ratio of 2.15, a current ratio of 0.87 and a quick ratio of 0.87. RadNet has a 12 month low of $19.95 and a 12 month high of $38.84. The stock has a market cap of $1.13 billion, a P/E ratio of 43.65 and a beta of 1.72. The company has a 50 day moving average of $22.24 and a 200 day moving average of $26.29.

A number of institutional investors have recently bought and sold shares of RDNT. O Shaughnessy Asset Management LLC increased its stake in shares of RadNet by 14.7% in the third quarter. O Shaughnessy Asset Management LLC now owns 2,662 shares of the medical research company’s stock valued at $78,000 after buying an additional 342 shares during the period. Thrivent Financial for Lutherans increased its stake in shares of RadNet by 1.2% in the fourth quarter. Thrivent Financial for Lutherans now owns 36,095 shares of the medical research company’s stock valued at $1,087,000 after buying an additional 444 shares during the period. UBS Asset Management Americas Inc. increased its stake in shares of RadNet by 1.3% in the third quarter. UBS Asset Management Americas Inc. now owns 42,013 shares of the medical research company’s stock valued at $1,231,000 after buying an additional 530 shares during the period. Royal Bank of Canada increased its stake in shares of RadNet by 9.0% in the third quarter. Royal Bank of Canada now owns 9,540 shares of the medical research company’s stock valued at $279,000 after buying an additional 785 shares during the period. Finally, Oregon Public Employees Retirement Fund increased its stake in shares of RadNet by 4.8% in the first quarter. Oregon Public Employees Retirement Fund now owns 17,628 shares of the medical research company’s stock valued at $394,000 after buying an additional 800 shares during the period. Hedge funds and other institutional investors own 68.74% of the company’s stock.

RadNet Company Profile (Get Rating)

RadNet, Inc, together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services.

Featured Stories

Get a free copy of the Zacks research report on RadNet (RDNT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RadNet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RadNet and related companies with MarketBeat.com's FREE daily email newsletter.